

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

30 May 2013

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(2 pages by email)

Dear Madam

PRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY CONFERENCE

- **Data from Phase 2a HIV trial to be presented at IAS Conference**
- **Expands on previously announced 'highly encouraging' results**
- **World's largest scientific conference on HIV/AIDS**

Biotron Limited (ASX: BIT) has been selected to present at the upcoming IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in early July.

The Company will present detailed anti-viral efficacy results from its recent phase 2a trial of lead drug candidate BIT225 on 21 HIV infected patients.

Over 5,000 delegates are expected to attend the conference, which is being held in Malaysia from 28 June to 3 July 2013. The event is held every two years and brings together leading scientists, clinicians, public health experts and community leaders to examine the latest developments in AIDS/HIV research.

In addition, Biotron will also present at the 'Towards an HIV Cure' symposium, which will be held in the 2 days immediately prior to IAS 2013.

Dr Miller commented: "This is an important opportunity to highlight and expand on the encouraging results we have achieved to date with BIT225 in HIV infected patients. This drug is a novel compound which is the first in a new class of antiviral drugs that may provide a new approach to the treatment of HIV."

The Company's phase 2a trial was conducted on 21 patients at an international clinical trial unit in Bangkok, Thailand.

Patients enrolled in the study were HIV-infected, with high levels of virus and good CD4+ T cell counts. None had previously received treatment with anti-retroviral drugs. Patients received either BIT225 (400 mg; twice daily) or placebo for a period of 10 days.

BIT225 is synergistic in vitro with commonly used anti-retroviral therapies and would potentially be used in conjunction with these treatments, and has the potential to be included in future virus elimination, or cure, strategies.

BIT225 is also in development for the treatment of Hepatitis C virus ('HCV') and has also recorded highly encouraging data in this indication. A phase 2a trial in HCV demonstrated that 100% of patients receiving BIT225 (400 mg) in combination with current standard of care therapies interferon and ribavirin had undetectable virus after 48 weeks. A further phase 2 trial of BIT225 in patients co-infected with both HIV and HCV is currently in progress.


Enquiries
Dr Michelle Miller
Managing Director
Biotron Limited
+61-2 9805 0488
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn7250